HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

trans- 4- (6,7- dimethoxyquinoxalin- 2ylamino)cyclohexanol sulfate

antineoplastic, inhibits PDGF receptor phosphorylation

Also Known As:

GN963

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinoxalines: 324
      - trans-4-(6,7-dimethoxyquinoxalin-2ylamino)cyclohexanol sulfate: 1

Experts

1.	Baker, Cheryl H: 1 article (07/2006)
2.	Caron, Alexis: 1 article (07/2006)
3.	Fidler, Isaiah J: 1 article (07/2006)
4.	Gallick, Gary E: 1 article (07/2006)
5.	Nesbit, Mark: 1 article (07/2006)
6.	Summy, Justin M: 1 article (07/2006)
7.	Trevino, Jose G: 1 article (07/2006)
8.	Zhang, Fahao: 1 article (07/2006)

Related Diseases

1.	Pancreatic Neoplasms (Pancreatic Cancer) 07/01/2006 - "Inhibition of PDGFR phosphorylation and Src and Akt activity by GN963 leads to therapy of human pancreatic cancer growing orthotopically in nude mice." 07/01/2006 - "We determined whether oral administration of GN963, alone or in combination with gemcitabine produces therapy against L3.6pl human pancreatic cancer cells growing orthotopically in nude mice. "
2.	Neoplasms (Cancer) 07/01/2006 - "Administration of GN963 inhibited PDGFR phosphorylation in both tumor and tumor-associated endothelial cells, decreased Src and Akt kinase activity in tumor cells, decreased microvessel density, and decreased tumor cell proliferation, while increasing apoptosis of tumor and tumor-associated endothelial cells. " 07/01/2006 - "In contrast, treatment with GN963 (100 mg/kg) or GN963 plus gemcitabine produced a 52% and 81% decrease in tumor volume, respectively. "
3.	Neoplasm Metastasis (Metastasis) 07/01/2006 - "GN963 plus gemcitabine completely inhibited the incidence of liver metastasis. "

Related Drugs and Biologics

1.	Phosphotransferases (Kinase)
2.	Gemcitabine

Related Therapies and Procedures

1.	Therapeutics
2.	Oral Administration